The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.

As is well known Muralitharan broke away from the LTTE and formed the paramilitary Karuna Group, which worked on behalf of the Sri Lankan Army during the war. The inclusion of Muralitharan alias “Col” ...